| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on November 6, 2002
From the Pacific Rim Electrophysiology Research Institute, Los Angeles, Calif (K.N.); the Royal Thai Air Force Medical Center, Bangkok, Thailand (G.V., L.C.); Johns Hopkins University School of Medicine, Baltimore, Md (M.M.); Mahidol University, Bangkok, Thailand (K.L., R.K., K.B.); Chulalongkorn University, Bangkok, Thailand (S.S.); and the Statistical Consultation and Research Center, University of Southern California School of Medicine, Los Angeles, Calif (M.Y.L., S.P.A.). * To whom correspondence should be addressed. E-mail: wee{at}pacificrimep.com.
Background--Sudden Unexplained Death Syndrome (SUDS) is the leading cause of death in young, healthy, Southeast Asian men. The role of an implantable cardioverter defibrillator (ICD) for mortality reduction in these patients remains unclear. Methods and Results--The Defibrillator Versus Conclusions--ICD treatment provides full protection from death related to primary VF in a SUDS population and is superior to
Revised on February 12, 2003
Accepted on February 18, 2003
Defibrillator Versus
Koonlawee Nademanee MD*,
-Blockers for Unexplained Death in Thailand (DEBUT). A Randomized Clinical Trial
-Blockers for Unexplained Death in Thailand (DEBUT) study is a randomized, clinical trial conducted in 2 phases (pilot study followed by the main trial) to compare the annual all-cause mortality rates among SUDS patients treated with
-blockers versus that among those treated with an ICD. A total of 86 patients who were SUDS survivors and probable SUDS survivors were randomized to receive an ICD or propranolol (20 patients were in the pilot study and 66 were in the main trial). The primary end point was death from all causes. The secondary end point was recurrent ventricular tachycardia/ventricular fibrillation (VF) or cardiac arrest. During the 3-year follow-up period of the main trial, there were 4 deaths; all occurred in the
-blocker group (P=0.02). Seven subjects in the ICD arm had recurrent VF, and all were effectively treated by the ICD. On the basis of the main trial results, the Data Safety Monitoring Board stopped the study. In total (both from the Pilot study and the main trial), there were 7 deaths (18%) in the
-blocker group and no deaths in the ICD group, but there were a total of 12 ICD patients receiving ICD discharges due to recurrent VF.
-blockade treatment.
This article has been cited by other articles:
![]() |
R. L. Verrier and M. E. Josephson Impact of Sleep on Arrhythmogenesis Circ Arrhythm Electrophysiol, August 1, 2009; 2(4): 450 - 459. [Full Text] [PDF] |
||||
![]() |
P.-S. Chen and S. G. Priori The Brugada Syndrome J. Am. Coll. Cardiol., March 25, 2008; 51(12): 1176 - 1180. [Full Text] [PDF] |
||||
![]() |
J. A. Ezekowitz, B. H. Rowe, D. M. Dryden, N. Hooton, B. Vandermeer, C. Spooner, and F. A. McAlister Systematic Review: Implantable Cardioverter Defibrillators for Adults with Left Ventricular Systolic Dysfunction Ann Intern Med, August 21, 2007; 147(4): 251 - 262. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Sacher, V. Probst, Y. Iesaka, P. Jacon, J. Laborderie, F. Mizon-Gerard, P. Mabo, S. Reuter, D. Lamaison, Y. Takahashi, et al. Outcome After Implantation of a Cardioverter-Defibrillator in Patients With Brugada Syndrome: A Multicenter Study Circulation, November 28, 2006; 114(22): 2317 - 2324. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-H. Kuck and S. Nisam ICD therapy: 'the sickest benefit the most...': what about the less sick? Europace, July 1, 2006; 8(7): 508 - 511. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nisam and G. Breithardt Lessons learned from neutral ICD trials Europace, June 1, 2006; 8(6): 393 - 397. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Goldberger and R. Lampert Implantable Cardioverter-Defibrillators: Expanding Indications and Technologies JAMA, February 15, 2006; 295(7): 809 - 818. [Abstract] [Full Text] [PDF] |
||||
![]() |
Additional Information JAMA, November 2, 2005; 294(17): E1 - E3. [Full Text] [PDF] |
||||
![]() |
J. P. Singh, W. J. Hall, S. McNitt, H. Wang, J. P. Daubert, W. Zareba, J. N. Ruskin, A. J. Moss, and and the MADIT-II Investigators Factors Influencing Appropriate Firing of the Implanted Defibrillator for Ventricular Tachycardia/Fibrillation: Findings From the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1712 - 1720. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kadish and M. Mehra Heart Failure Devices: Implantable Cardioverter-Defibrillators and Biventricular Pacing Therapy Circulation, June 21, 2005; 111(24): 3327 - 3335. [Full Text] [PDF] |
||||
![]() |
B. Belhassen, A. Glick, and S. Viskin Efficacy of Quinidine in High-Risk Patients With Brugada Syndrome Circulation, September 28, 2004; 110(13): 1731 - 1737. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Hermida, I. Denjoy, J. Clerc, F. Extramiana, G. Jarry, P. Milliez, P. Guicheney, S. Di Fusco, J.-L. Rey, B. Cauchemez, et al. Hydroquinidine therapy in Brugada syndrome J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1853 - 1860. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Zipes The year in electrophysiology J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1306 - 1314. [Full Text] [PDF] |
||||
![]() |
R. Krittayaphong, G. Veerakul, K. Nademanee, and C. Kangkagate Heart rate variability in patients with Brugada syndrome in Thailand Eur. Heart J., October 1, 2003; 24(19): 1771 - 1778. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |